Arcellx, Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical tr…
Biotechnology
US, Gaithersburg [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -9.94 | 5.46 | 6.06 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -76.18 | 4.50 | -18.89 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.38 | 9.41 | 9.28 | |
| Cash | -18.96 | 10.88 | 13.43 | |
| Capex | -20.42 | -0.12 | -0.10 | |
| Free Cash Flow | -28.26 | -0.73 | 1.01 | |
| Revenue | -38.40 | 0.74 | 1.21 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.97 | 0.98 | 0.99 | |
| Operating Margin | 69.56 | -0.40 | 0.24 | |
| ROA | -61.61 | < 0.005 | 0.02 | |
| ROE | -64.54 | -0.01 | 0.04 | |
| ROIC | 8.54 | -0.03 | 0.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ACLX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ACLX is permitted for members.
6
Leverage & Liquidity